Biostem Technologies Inc
OTC:BSEM
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Biostem Technologies Inc
OTC:BSEM
|
186.9m USD |
41%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
699.1B USD |
14%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-2%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
12%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
211.2B CHF |
9%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
184.2B CHF |
13%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
166.2B GBP |
7%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
193.3B USD |
16%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-51%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
133.5B USD |
4%
|
Biostem Technologies Inc
Glance View
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Biostem Technologies Inc's most recent financial statements, the company has ROA of 41.2%.
You don't have any saved screeners yet